Senses Disorder TRIZ Cases

A topical dapsone gel formulation reduces papulopustular lesions while minimizing systemic side effects.

Serum-free culture of mesenchymal stem cells increases TSG-6 production to suppress fibrosis and inflammation.

A tricyclic compound modulates the glucocorticoid receptor to treat inflammation while mitigating bone loss and osteoporosis.

Intronic recognition elements enable small molecule splicing modifiers to induce alternative splicing patterns in precursor RNA transcripts.

Fusing Fab fragments to serum-binding domains extends half-life while maintaining tissue penetration.

Soluble carbonates neutralize gastric acid to enhance oral drug dissolution, resolving slow absorption trade-offs.

Segmented genetic screening identifies Factor H and CFHR5 variants to resolve diagnostic accuracy limits in age-related macular degeneration.

Incubating blood samples to isolate exosomes, resolving tolerability and efficacy trade-offs.

Local quality modifications to rAAV capsid proteins enhance barrier crossing and retinal infectivity, resolving delivery limitations of wild-type vectors.

Novel Streptococcus salivarius strain LMG P-31813 replaces surgical ventilation tubes by restoring middle ear microbiota balance and inhibiting pathobionts.

Engineered plant cells express microbial enzymes to synthesize long-chain polyunsaturated fatty acids, replacing unsustainable fish-derived sources.

N-acetylcysteine amide overcomes limited membrane permeability of vitamins E and C by enhancing cellular uptake.

Amino isoquinolinyl amide compounds modulate kinase activity to reduce intraocular pressure, addressing receptor desensitization and inadequate disease control.

IL-1 genotype stratification predicts recurrent cardiac events in 60% of cases, enabling personalized risk assessment beyond standard LDL-C monitoring.

Sigma-1 receptor activators stabilize IP3R1 conformation to enhance calcium efflux, addressing mitochondrial dysfunction in Wolfram syndrome.

Precipitation from Polysorbate 80 yields a kinetically stable crystalline form that resists conversion in aqueous suspensions.

Segmented naphthalene sulfonylurea derivatives selectively block EP4 receptors to reduce pain while avoiding gastrointestinal toxicity.

Silver-cobalt nanozymes in hydrogel matrices deliver sustained antimicrobial action against drug-resistant corneal infections.

Segmented punctal implants with asymmetric geometry maintain retention and reduce intraocular pressure.

Segmenting complement inhibition via MASP-2 targets prevents indiscriminate tissue damage while controlling initiation steps.

Peroxiredoxin II inhibitor reduces VEGFR activation to suppress angiogenesis while avoiding tumor cell aggression and drug delivery hindrance.

A novel polymorph form II of the compound achieves 99.999% purity, reducing cumulative impurity exposure during long-term oral dosing.

A bispecific fusion protein combines complement and VEGF inhibiting domains into a single therapeutic agent.

Heteroaryl-tetrahydrothiophene compounds block A3 adenosine receptors, reducing intraocular pressure while protecting retinal ganglion cells from degeneration.

Rotating processing surfaces form thin film fluid to separate biologically ingestible microparticles, reducing energy consumption and contamination risks.

Novel imidazolecarboxamides inhibit fatty acid amide hydrolase through specific structural modifications.

Recombinant human C1 esterase inhibitor proteins resolve short half-life bottlenecks by achieving extended serum stability via optimized host cell sialylation.

Alpha2-selective Na,K-ATPase inhibitors reduce intraocular pressure while avoiding cardiotoxicity associated with non-selective cardiac glycosides.

Cistanche tubulosa extract protects retinal pigment epithelial cells from oxidative damage.

Substituted 3-azolopropionic acid compounds antagonize alphaV integrins to treat fibrotic conditions and cancer.

Optimized 3,4-dihydrobenzoxazine compounds inhibit VR1 activity while reducing side effects and resistance associated with conventional analgesics.

Segmented DNase1 and RNase1 chains linked via an Fc domain resolve steric hindrance while extending serum half-life to treat systemic lupus erythematosus.

Segmented chambers and sealable elements contain treatment fluids to prevent seepage while enabling controlled dispensing onto the ocular region.

Novel n-acyl-n'-phenylpiperazine compounds lower blood retinol binding protein 4 levels by inhibiting complex formation with transthyretin.

Exosome-based neural stem cell microparticles resolve immunogenicity and tumor risks while enabling scalable production.

Nitric oxide releasing prostaglandin derivatives increase aqueous humor outflow through dual pathways.

Vaccine comprising angiotensin peptides bound to a carrier protein elicits a humoral immune response.

Identifying Dear receptor polymorphisms improves genetic marker precision, resolving inadequate clinical results for angiogenesis modulation.

IGF-1R inhibitors target the overstimulated insulin-like growth factor 1 receptor pathway to reduce inflammation severity in patients.

N-hydroxyamide derivatives inhibit specific matrix metalloproteinases to treat inflammatory diseases without musculoskeletal side effects.

A diethylamine solvate forms a crystalline structure from an amorphous SGLT inhibitor compound.

Anti-transferrin receptor antibodies optimize binding affinity to resolve the trade-off between receptor strength and brain uptake for neurological treatments.

A prime editing guide RNA system directs Cas9 nickase and reverse transcriptase to target mutated DNA sequences.

A collagen type II alpha-1 derived peptide sequence inhibits angiogenesis and reduces corneal opacity.

An iontophoretic device drives riboflavin across the corneal epithelium, resolving limited topical penetration while avoiding invasive tissue trauma.